(Q35915686)

11 August 2017

1 reference

title

Optimizing factor prophylaxis for the haemophilia population: where do we stand? (English)

1 reference

11 August 2017

0 references

1

Blanchette VS

1 reference

11 August 2017

Manco-Johnson M

2

1 reference

11 August 2017

Santagostino E

series ordinal

3

1 reference

11 August 2017

Ljung R

series ordinal

4

1 reference

11 August 2017

publication date

1 October 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

10 Suppl 4

1 reference

11 August 2017

page(s)

97-104

1 reference

The hemophilias--from royal genes to gene therapy

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2004.00998.X

Consensus perspectives on prophylactic therapy for haemophilia: summary statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2004.00998.X

Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2004.00998.X

Haemophilia prophylaxis in young patients--a long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2004.00998.X

Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group. secretariat.haemophiles@cch.ap-hop-paris.fr

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2004.00998.X

Prophylactic treatment in Sweden--overtreatment or optimal model?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2004.00998.X

Can haemophilic arthropathy be prevented?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2004.00998.X

Prophylactic factor replacement in hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2004.00998.X

When should prophylactic treatment in patients with haemophilia A and B start?--The German experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2004.00998.X

The impact of prophyactic treatment on children with severe haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2004.00998.X

Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2004.00998.X

The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2004.00998.X

What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2004.00998.X

Long-term outcome of individualized prophylactic treatment of children with severe haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2004.00998.X

Port-A-Cath usage in children with haemophilia: experience of 53 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2004.00998.X

Central venous catheters in children with haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2004.00998.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2004.00998.X

A prospective clinical trial of implantable central venous access in children with haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2004.00998.X

Long‐term safety and feasibility of arteriovenous fistulae as vascular accesses in children with haemophilia: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2004.00998.X

Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2004.00998.X

Development and testing of an instrument to assess the Quality of Life of Children with Haemophilia in Europe (Haemo-QoL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2004.00998.X

Development of a health-related quality of life measure for boys with haemophilia: the Canadian Haemophilia Outcomes--Kids Life Assessment Tool (CHO-KLAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2004.00998.X

Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2004.00998.X

Barriers to compliance with prophylaxis therapy in haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2004.00998.X

Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2004.00998.X

10.1111/J.1365-2516.2004.00998.X

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference